Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Figure S1 - Docosahexaenoic Acid Decreases Pro-Inflammatory Mediators in an <i>In Vitro</i> Murine Adipocyte Macrophage Co-Culture Model by Anna A. De Boer (510740)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on survival, body weight and body temperature within 48 hours after cecal ligation and puncture (CL... by Daniel Siegl (717509)

Training steps of the improved YOLOv4-Tiny. by Fuxing He (19555871)

Effectiveness of E cytotoxicity presented as a half maximal growth inhibitory concentration (CC₅₀). by Anna Kalota (7415)

TG6-44 treatment leads to a decrease in NP-positive cells and altered expression patterns of NP in A/X31 infected THP-1 cells. by Juan A. De La Cruz (11154187)

Contemporary mean inundation fraction in the Amazon basin. by Nic Gedney (19762301)

The mean <i>z</i>-coordinate error decreasing percentages (%) of SSI-RIK compared to EM-SFM, CSF and RIK, when the sequence sizes vary from 15 to 50 with an equal interval 5. by Ya-Ping Wang (44525)

“…<p>The mean <i>z</i>-coordinate error decreasing percentages (%) of SSI-RIK compared to EM-SFM, CSF and RIK, when the sequence sizes vary from 15 to 50 with an equal interval 5.…”

Least squares mean (LSM) + standard error (SE) of C3 concentration, ACH50 and CH50 values in different haplotypic combinations among 354 Chinese Holstein cows. by Yonghui Wang (287491)

SHIP-1 PRD region is necessary and sufficient to decrease NOD2-induced NF-κB activity. by Claude Condé (150801)

Tannic acid blocks an early step of HCV entry. by Shuanghu Liu (307907)

“…Huh7.5 cells were inoculated with HCV JFH1-AM120-Rluc at a MOI of 10 for one hour at 4°C in presence of 50 μM of tannic acid, 500 μg/ml of heparin or no inhibitor as a control. …”

Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif by Zijing Ran (11429935)

“…</p>Results<p>ULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. …”

Silencing of Rap1A decreases ERK and p38 activation. by Yougen Wu (830191)

Inhibition of ACC leads to decreased de novo lipogenesis in both U87 and U87 EGFRvIII but reduced the number of U87 EGFRvIII cells to a greater extent. by Jessica E. C. Jones (541168)

Decreased miR-29b/c in GC tissue samples. by He Cui (229445)